SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Ellipse

Implantable Cardioverter Defibrillator

How It Works

How it Works

Greater Programming Flexibility with DeFT Response™ Technology

DeFT Response technology offers the most adaptable, non-invasive programming options to rapidly optimize therapy performance to each patient’s unique needs.

DeFT Response technology is only available in Abbott high-voltage devices.

With DeFT Response technology, physicians gain:

  • Non-invasive programming flexibility in the management of DFTs to ensure adequate safety margins with exceptional energy delivery.
  • More options for adapting to changing patient conditions following implant with or without induction testing. These options are intended to help physicians prevent fluctuations in DFTs and a diminished safety margin.1-10
  • Pulse width programmability, available only from Abbott, which lets physicians choose the duration of each phase of the shock from 2.0 ms to 6.5 ms with or without induction testing. This method lets physicians precisely match the biphasic waveform to a patient’s unique membrane response time.11-14

The physiologic variability in the patient population means that optimal truncation times are often different between individuals. By varying waveform pulsewidths, DeFT Response technology allows flexibility and patient-specific programming options.

Line graph showing the shock truncation, voltage and membrane response of the Ellipse ICD.

Added Protection with SecureSense RV Lead Noise Discrimination Algorithm

The SecureSense™ RV lead noise discrimination algorithm offers added protection from lead noise to reduce unnecessary therapy. It can be programmed to alert a health care professional via Merlin.net™ Patient Care Network (PCN), allowing for more rapid, clinical decision making. Programmable alerts notify the patient and clinician when lead noise is detected.

Compare sensed events on primary and secondary channels. Compare rate, diagnose lead noise, inhibit or delivery therapy.

Improved Therapy Assurance
with DynamicTx
Over-Current Detection Algorithm

DynamicTx™ over-current detection algorithm is designed to provide enhanced patient safety and improved therapy assurance in the event of compromised high-voltage lead integrity, and is only available in the Abbott high-voltage portfolio.

Note

  • Alternate vector options available: RV-Can and RV-SVC
  • Vector switching sequence varies based on programmed configuration

Requirements

  • Dual coil lead
  • Programmed configuration not RV-can
Flow chart showing 4 steps: HV Shock attempted, high current detected, alternate vector switch, and HV shock delivered.
Manuals & Resources

Manuals & Resources

Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Shukla, H. H., Flaker, G. C., Jayam, V., & Roberts, D. (2003). High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. PACE, 26(1 Pt 1), 44-48.
  2. Tokano, T., Pelosi, F., Flemming, M., Horwood, L., Souza, J. J., Zivin, A., . . . Strickberger, S. A. (1998). Long-term evaluation of the ventricular defibrillation energy requirement. Journal of Cardiovascular Electrophysiology, 9, 916-920.
  3. Wase, A., Basit, A., Nazir, R., Jamal, A., Shah, S., Khan, T., . . . McCullough, P. A. (2004). Impact of chronic kidney disease upon survival among implantable cardioverter defibrillator recipients. Journal of Interventional Cardiac Electrophysiology, 11(3), 199-204.
  4. Stephenson, E. A., Cecchin, F., Walsh, E. P., & Berul, C. I. (2005). Utility of routine follow-up defibrillator threshold testing in congenital heart disease and pediatric populations. Journal of Cardiovascular Electrophysiology, 16(1), 69-73.
  5. Nielsen, T. D., Hamdan, M. H., Kowal, R. C., Barbera, S. J., Page, R. L., Joglar, J. A. (2001). Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. American Journal of Cardiology, 88(4), 446-448.
  6. Pelosi, F. Jr, Oral, H., Kim, M. H., Sticherling, C., Horwood, L., Knight, B. P., . . . Strickberger, S. A. (2000). Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. Journal of Cardiovascular Electrophysiology, 11(7), 736-740.
  7. Crystal, E., Ovsyshcher, I. E., Wagshal, A. B., Katz, A., & Ilia, R. (2002). Mexiletine related chronic defibrillation threshold elevation: case report and review of the literature. PACE, 25(4 Pt 1), 507-508.
  8. McBride, B. F., White, C. M., Kalus, J. S., Guertin, D. C., Clyne, C. A., Baker, W. L., & Kluger, J. (2008). The impact of carvedilol on the defibrillation threshold. Heart & Lung: Journal of Acute & Critical Care, 37(1), 67-71.
  9. Carnes, C. A., Pickworth, K. K., Votolato, N. A., & Rarman, S. V. (2004). Elevated defibrillation threshold with venlafaxine therapy. Pharmacotherapy, 24(8), 1095-1098.
  10. Shinlapawittayatorn, K., Sangnoon, R., Chattipakorn, S., Suriyasataporn, W., & Chattipakorn, N. (2005). Sildenafil citrate markedly increases defibrillation threshold in swine. Journal of the American College of Cardiology, 45(3), 110A.
  11. Keane, D., Aweh, N., Hynes, B., Sheahan, R. G., Cripps, T., Bashir, Y., . . . Kroll, M. K. (2007). Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. PACE, 30(5), 596-602.
  12. Natarajan, S., Henthorn, R., Burroughs, J., Esberg, D., Zweibel, S., Ross, T., . . . Oza, A. (2007). “Tuned” defibrillation waveforms outperform 50/50% tilt defibrillation waveforms: a randomized multicenter study. PACE, 30(11), 1424.
  13. Denman, R. A., Umesan, C., Martin, P. T., Forbes, R. N., Kroll, M. W., Anskey, E. J., & Burnett, H. E. (2006). Benefit of millisecond waveform durations for patients with high defibrillation thresholds. Heart Rhythm, 3(5), 536-541.
  14. Mouchawar, G., Kroll, M., Val-Mejias, J. E., Schwartzman, D., McKenzie, J., Fitzgerald, D., . . . Syed, Z. (2000). ICD waveform optimization: a randomized, prospective, pair-sampled multicenter study. PACE, 23(11 Pt 2), 1992-1995.

MAT-2205139 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0